Regina Mbugua

Dr. Regina Mbugua


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
RMRegina Mbugua
Regina Mbugua
ENEliud Mwaniki Njagi
Eliud Mwaniki Njagi
CNChrispus Mutuku Ngule
Chrispus Mutuku Ngule
PMPeter Mwitari
Peter Mwitari
Globally, approximately 13% of all deaths annually are attributed to cancer. Surgery, radiation and chemotherapy are the current treatment techniques for cancer, however these methods are expensive, have high failure rates and have been associated with detrimental side effects. Plant derived products could be good candidates in alleviating challenges being experienced with these current methods. This study aimed at evaluating the phytochemistry, antiproliferation potential, and probable mechanism of action of Albizia gummifera , Rhamnus staddo and Senna didymobotrya plant extracts. Phytochemical screening was done as per standard procedures. The common 3– (4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium (MTT) dye was used in the determination of the antiproliferative activity of the extracts. Extracts induction of VEGF (angiogenesis) and p53 (apoptosis) genes’ expression was evaluated using Real Time Polymerase Chain Reaction. Phytochemical screening revealed presence of alkaloids, tannins, glycosides, flavonoids, terpenes, phenolics and saponins in the plants extracts. A. gummifera’s stem bark methanol: dichloromethane extract had the highest activity against the cancerous cell lines tested: HCC1395 (IC 50 6.07±0.04μg/ml), DU145 (IC 50 3.34±0.05μg/ml), CT26 (IC 50 5.78±0.08μg/ml) and Hep2 (IC 50 7.02±0.01μg/ml). R. staddo root bark methanol: dichloromethane extract had an IC 50 value of 15.71±0.04μg/ml on HCC, 9.81±0.09μg/ml on Hep2 and 11.14±0.39μg/ml on CT26. S. didymobotrya root bark methanol: dichloromethane extract inhibited HCC with an IC 50 of 65.06±0.07μg/ml, CT26 with an IC 50 of 15.71±0.04μg/ml and Hep2 with an IC 50 of 62.10±0.11μg/ml. From the results obtained, the plants exhibited selective toxicity to cancer cells while sparing the normal cells (SI ≥ 3). A. gummifera and S. didymobotrya and R. staddo plant extracts upregulated p53 and down-regulated VEGF genes. In conclusion, this study confirms that these plant extracts could be potential candidates for development of drugs for the management of breast, prostrate, colorectal and throat cancer.

25 August 2022 in European Journal of Medicinal Plants
Verified
Journal Article
Closed access
PDF file
RMRegina Mbugua
Regina Mbugua
ENEliud M. Njagi
Eliud M. Njagi
CNChrispus M. Ngule
Chrispus M. Ngule
PMPeter G. Mwitari
Peter G. Mwitari
Globally, approximately 13% of all deaths annually are attributed to cancer. Surgery, radiation and chemotherapy are the current treatment techniques for cancer; however, these methods are expensive, have high failure rates and have been associated with detrimental side effects. Plant derived products could be good candidates in alleviating challenges being experienced with these current methods. This study aimed at evaluating the phytochemistry, antiproliferation potential, and probable mechanism of action of Albizia gummifera, Rhamnus staddo and Senna didymobotrya plant extracts. The 3– (4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium (MTT) assay dye was used in the determination of the antiproliferative activity of the extracts. Extracts induction potential of p53 (apoptosis) and VEGF (angiogenesis) genes’ expression was evaluated using Real Time PCR. Phytochemical screening was done as per standard procedures. Several plant extracts exhibited antiproliferative activity against the cancerous cell lines tested showing selective toxicity to cancer cells while sparing the normal cells (SI ≥ 3). An upregulation of p53 and down-regulation VEGF genes was observed. Phytochemical screening revealed presence of pharmacologically important phytochemicals in the plant’s extracts. The study findings suggest exploitation of these plant extracts as potential candidates for development of drugs for the management of breast and prostate cancer.